BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25910573)

  • 1. Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature.
    Fouad M; Abdel-Rahman O
    Arab J Gastroenterol; 2015 Jun; 16(2):40-5. PubMed ID: 25910573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
    Abdel-Rahman O; Elsayed ZA
    Dig Dis Sci; 2013 Dec; 58(12):3389-96. PubMed ID: 24046163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.
    Yoo SH; Jang JW; Kwon JH; Jung SM; Jang B; Choi JY
    Clin Mol Hepatol; 2016 Dec; 22(4):458-465. PubMed ID: 28081589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
    Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y
    Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
    Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
    Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.
    Liu B; Zhang Y; Chen H; Li W; Tsochatzis E
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013345. PubMed ID: 34981511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization.
    Yu SJ; Lee JH; Jang ES; Cho EJ; Kwak MS; Yoon JH; Lee HS; Kim CY; Kim YJ
    Radiology; 2013 May; 267(2):638-47. PubMed ID: 23440326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis.
    Zhang SS; Liu JX; Zhu J; Xiao MB; Lu CH; Ni RZ; Qu LS
    Jpn J Clin Oncol; 2019 Jul; 49(7):646-655. PubMed ID: 30968933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
    Chen ZX; Jian ZW; Wu XW; Wang JC; Peng JY; Lao XM
    Cancer Med; 2019 Sep; 8(11):5097-5107. PubMed ID: 31313476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative.
    Wang K; Jiang G; Jia Z; Zhu X; Ni C
    Medicine (Baltimore); 2018 Jun; 97(22):e10940. PubMed ID: 29851833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
    Lin XJ; Li QJ; Lao XM; Yang H; Li SP
    BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation.
    Mishra G; Dev A; Paul E; Cheung W; Koukounaras J; Jhamb A; Marginson B; Lim BG; Simkin P; Borsaru A; Burnes J; Goodwin M; Ramachandra V; Spanger M; Lubel J; Gow P; Sood S; Thompson A; Ryan M; Nicoll A; Bell S; Majeed A; Kemp W; Roberts SK;
    BMC Cancer; 2020 May; 20(1):483. PubMed ID: 32471447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
    Tong H; Wei B; Chen S; Xie YM; Zhang MG; Zhang LH; Huang ZY; Tang CW
    Oncotarget; 2017 Jul; 8(29):48303-48312. PubMed ID: 28430638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence.
    Yan Q; Ni J; Zhang GL; Yao X; Yuan WB; Zhou L; Zheng SS
    Chin Med J (Engl); 2013 Mar; 126(5):855-9. PubMed ID: 23489790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.